XOMA Royalty Corporation Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements (Tables)

6 Months Ended

Jun. 30, 2023

The following table summarizes the royalty and commercial payment receivable activities during the six months ended June 30, 2023 (in thousands):


	Short-Term		Long-Term
Balance at January 1, 2023	$	2,366	$	63,683
Acquisition of royalty and commercial payment receivables:
Aptevo		—		9,650
LadRx		—		6,000
Receipt of royalty and commercial payments:
Affitech		(2,366)
Aptevo				(568)
Impairment of royalty and commercial payment receivables:
Bioasis				(1,575)
Reclassification to short-term royalty and commercial payment receivables:
Affitech		4,958		(4,958)
Balance at June 30, 2023	$	4,958	$	72,232